Orthobiologics Market Research Report Segmentation by Product (Demineralized Bone Matrix, Allograft, Bone Morphogenetic Protein {BPM}, Viscosupplementation Products, Synthetic Bone Substitutes and Others), by Application (Osteoarthritis & Degenerative Arthritis, Spinal Fusion, Fracture recovery, Soft Tissue Injuries, Maxillofacial & Dental Applications) by End User (Hospitals, Ambulatory Centres, Research & Academic Institute, Dental Clinics) and Region - Size, Share, Growth Analysis | Forecast (2024 2030)

GLOBAL ORTHOBIOLOGICS MARKET SIZE (2024 - 2030)

As per the findings presented by Our Research, the Global Orthobiologics Market attained a valuation of USD 5.49 billion, with a projected escalation to a market size of USD 6.98 billion by the culmination of 2030. Anticipated over the forecast duration spanning from 2024 to 2030, the market is poised to register a Compound Annual Growth Rate (CAGR) of 3.5%.

Regenerative cellular therapies are synonymous with orthobiologics. These products encompass or generate growth factors, facilitating tissue repair, alleviating pain, and contributing to the restoration of normal function. Various forms of orthobiologics, each with its distinct mode of action, are available in the market. Autologous stem cells, sourced from the patient's own body, undergo division under optimal conditions to produce progenitor cells. Orthobiologics find application in treating diverse conditions, including fracture rehabilitation, spinal fusion, and more. Additionally, they are accessible for various body parts such as the hip, knee, ankle, spine, wrist, and others, primarily employed to expedite injury recovery.

Numerous multinational corporations are directing their efforts towards the development of orthobiologics products. The manifold advantageous attributes of orthobiologics have recently found application in medical science. The global orthobiologics market is witnessing robust expansion due to heightened demand for products that are both time and cost-efficient. Projected factors fuelling market growth include recent advancements in the sector and expanding healthcare explorations during the forecast period.

The growth in the global elderly population, susceptible to conditions like osteoarthritis, contributes significantly to the market's expansion. Other driving factors include heightened awareness of orthobiologics and an increased demand for enhanced therapeutic options. The surge in obesity and the frequency of sports and road accidents are additional pivotal factors propelling the orthobiologics market's growth.

Covid-19 Impact on the Orthobiologics Market The ongoing coronavirus pandemic has presented unprecedented challenges to healthcare institutions and various corporate sectors since its onset. Notably, several countries, including the United States, implemented temporary restrictions on elective surgeries between March and May 2020 to curb the virus's spread and preserve vital resources like Personal Protective Equipment (PPE) and ventilators. These measures led to a growing number of orthopaedic patients being deprived of medical care during the crisis, creating obstacles to the industry's stable expansion.

A substantial surgery backlog is anticipated due to the significant delay in treatment. Post-pandemic projections indicate that the backlog in orthopaedic surgery for joint replacements and spinal fusions may exceed one million, potentially increasing the demand for orthobiologic devices as a viable non-surgical treatment option for individuals with orthopaedic issues in the post-COVID era.

MARKET DRIVERS

The growth of the healthcare sector is propelling the orthobiologics market.

The global healthcare sector is expanding as individuals become more cognizant of effective healthcare treatments, coupled with the rise in disposable income. The orthobiologics market is experiencing global growth owing to the substantial development of the healthcare industry in emerging economies. Increased research expenditure on orthopaedic biologic solutions signifies a prospective surge in orthobiologics in the coming years. The growing geriatric population, combined with the current population's adoption of a sedentary lifestyle, is expected to significantly boost the orthobiologics market throughout the projected period. The increasing number of collaborations between industry and institutions is poised to propel a diverse range of pipeline products into gaining traction in the orthobiologics market.

The market is expanding due to the rising incidence of disorders linked to lifestyle changes.

Over the forecast period, the global orthobiologics market is expected to be driven by the escalating urbanization and hectic lifestyles that necessitate prompt and efficient orthopaedic solutions promoting rapid recovery and reducing hospital visits. The market is projected to witness steady growth due to the rising prevalence of lifestyle-related diseases, trauma cases, and chronic ailments. Furthermore, the increasing occurrences of sports injuries, accidents, and the rising prevalence of obesity and arthritis are anticipated to significantly enhance the orthobiologics market throughout the forecast period. Analysts within the industry express high optimism regarding the expansion of orthobiologics.

MARKET RESTRAINTS

Stringent regulations and intricate procedures are hindering market expansion.

Throughout the forecast period, stringent regulatory standards associated with novel research solutions, coupled with the complexities in paving the way for new orthobiologics solutions due to variable cost constraints, are anticipated to impede the orthobiologics market in emerging nations. Additionally, the higher associated costs are predicted to act as a hindrance to market growth.

The market's growth is impeded by elevated costs and insufficient reimbursements.

Despite favorable growth conditions, challenges such as increased complications among patients after intradiscal orthobiologic injection and high surgical costs among patients with comorbidities may limit the industry's market share in the upcoming years.

High costs and inadequate reimbursements for orthobiologics goods and procedures pose significant challenges, limiting the market's growth. The high cost of orthobiologics treatments and products stands out as a major obstacle to the market's expansion.

Orthobiologics Market by Product

• Demineralized Bone Matrix
• Allograft
• Bone Morphogenetic Protein (BMP)
• Viscosupplementation Products
• Synthetic Bone Substitutes and Others

In 2021, the orthobiologics market was predominantly led by the Viscosupplementation product category, primarily due to its favorable reimbursement landscape, having obtained approval from the US FDA. Moreover, the reimbursement policy for viscosupplementation products in France is well-established, further contributing to their market dominance.

Additionally, the Viscosupplementation product segment is anticipated to exhibit the highest growth during the forecast period, with a projected Compound Annual Growth Rate (CAGR) of 4.8% from 2024 to 2030. This growth can be attributed to factors such as an aging population, a rise in osteoarthritis prevalence, and an increase in lifestyle-related conditions like obesity.

Orthobiologics Market by Application

• Osteoarthritis & Degenerative Arthritis
• Spinal Fusion
• Fracture Recovery
• Soft Tissue Injuries
• Maxillofacial & Dental Applications

In the application segment, spinal fusion claimed more than half of the market share. The demand for orthobiologic products in spinal fusion procedures was fueled by the utilization of demineralized bone matrices, bone morphogenetic proteins, autografts, and allografts. The application segment's increased market share is attributed to the advantages of orthobiologic products in spinal fusion, including rapid cell stimulation for bone production, reduced hospital stay, and fewer hospital visits. The presence of third-party insurances for fusion enhancement products also contributed to the segment’s growth.

Orthobiologics Market by End-User

• Hospitals
• Ambulatory Centers
• Research & Academic Institutes
• Dental Clinics

Hospitals dominate the end-user segment, driven by the growing acceptance of orthobiological products in various spinal and reconstructive procedures conducted within hospital settings. The substantial market share is expected to persist due to specialized patient care and the wide availability of orthobiologics in hospitals. Factors such as high patient turnover, frequent readmissions, and significant operation volumes contribute to the segment's growth. The supportive infrastructure in hospitals facilitates precise operating procedures, further supporting the segment’s expansion.

Orthobiologics Market by Region

• North America
• Europe
• Asia-Pacific
• Latin America
• The Middle East and Africa

North America led the global orthobiologics market in 2021, closely followed by Europe and the Asia-Pacific. The region's leadership is attributed to the presence of major firms committed to promoting quality care and implementing new product development strategies. Reimbursement eligibility for soft tissue healing and fusion improvement products significantly contributes to the regional market share. Asia-Pacific holds a substantial share, driven by factors such as an aging population, increased disposable income, heightened research and innovation activities, and greater awareness of orthobiologics usage. The region's growth is further propelled by the rising incidence of sports and road-related injuries.

Orthobiologics Market by Company

1. Medtronic
2. Smith & Nephew plc
3. Stryker Corporation
4. DePuy Synthes, Inc.
5. Genzyme

• Leading companies, including Medtronic, Smith & Nephew plc, Stryker Corporation, DePuy Synthes, Inc., and Genzyme, heavily incorporate new product development, collaborations, distribution enhancement tactics, mergers and acquisitions, and frequent product approvals. For instance, NuVasive Inc. launched AttraX Putty in May 2020 to expand its product portfolio and gain a competitive edge.

Notable Happenings in the Ortho Biologics Market in the Recent Past

Product Launch

In March 2022, SeaSpine introduced the NorthStar cervical facet fusion and the Flash Speed lumbar facet fusion, aiming to expedite procedural operations and optimize fusion regions.

Joint Venture

In February 2022, Ortho Regenerative Technologies Inc. signed a Material Transfer Agreement with an undisclosed global medical company for the exclusive use of their patented platelet-rich plasma system in Ortho's future ORTHO-R rotator cuff tear repair procedure.

Collaborations

In June 2021, DePuy Synthes collaborated with Expanding Innovations Inc. for the X Pac Expandable Lumbar Cage System in the United States, providing a comprehensive procedural solution for lumbar degenerative and minimally invasive spine segments.